Sarepta Therapeutics (SRPT) Given Coverage Optimism Score of 0.14

News headlines about Sarepta Therapeutics (NASDAQ:SRPT) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sarepta Therapeutics earned a news impact score of 0.14 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.5558294336776 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media headlines that may have impacted Accern’s analysis:

Shares of Sarepta Therapeutics (SRPT) traded down $0.42 during mid-day trading on Friday, reaching $55.25. 1,713,742 shares of the company’s stock were exchanged, compared to its average volume of 1,778,143. Sarepta Therapeutics has a 52-week low of $26.26 and a 52-week high of $57.57. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.66. The firm had revenue of $45.95 million for the quarter, compared to analyst estimates of $41.29 million. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. During the same quarter in the previous year, the business posted ($0.95) EPS. sell-side analysts forecast that Sarepta Therapeutics will post -3.11 EPS for the current fiscal year.

Several research firms recently weighed in on SRPT. Credit Suisse Group restated an “outperform” rating and set a $81.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Robert W. Baird restated a “buy” rating and set a $101.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, October 17th. William Blair restated an “outperform” rating on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Piper Jaffray Companies restated an “overweight” rating and set a $55.00 target price (up previously from $50.00) on shares of Sarepta Therapeutics in a report on Thursday, September 7th. Finally, J P Morgan Chase & Co restated a “hold” rating on shares of Sarepta Therapeutics in a report on Monday, September 25th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and seventeen have issued a buy rating to the company’s stock. Sarepta Therapeutics currently has an average rating of “Buy” and a consensus target price of $64.14.

In related news, CEO Douglas S. Ingram bought 38,138 shares of the business’s stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average price of $52.44 per share, for a total transaction of $1,999,956.72. Following the purchase, the chief executive officer now owns 420,196 shares in the company, valued at approximately $22,035,078.24. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Shamim Ruff sold 11,500 shares of the company’s stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $50.00, for a total transaction of $575,000.00. The disclosure for this sale can be found here. Corporate insiders own 9.60% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Insider Buying and Selling by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with's FREE daily email newsletter.

Leave a Reply